Kornblau and colleagues reported that simultaneous activation of protein kinase B (AKT), protein kinase Cα (PKC α), and extracellular signal regulated kinase (ERK) is very detrimental to the AML patient (28). The gene discussed is PRRT2; the disease is acute myeloid leukemia.